background
antisens
oligom
induc
exon
skip
aim
reduc
sever
duchenn
muscular
dystrophi
redirect
splice
prerna
process
caus
mutat
bypass
shorter
partial
function
becker
muscular
dystrophylik
dystrophin
isoform
produc
normal
exon
gener
target
restor
dystrophin
read
frame
howev
appreci
subset
dystrophin
mutat
intraexon
therefor
potenti
compromis
oligom
effici
necessit
personalis
oligom
design
patient
although
antisens
oligom
easili
personalis
remain
unclear
whether
patient
polymorph
within
antisens
oligom
target
sequenc
requir
costli
process
produc
valid
patient
specif
compound
method
report
preclin
test
panel
splice
switch
antisens
oligom
design
excis
exon
dystrophin
transcript
normal
dystroph
patient
cell
patient
cell
harbour
singl
base
insert
exon
lie
within
target
sequenc
oligom
shown
effect
remov
exon
result
anticip
mutat
would
compromis
oligom
bind
effici
howev
show
despit
mismatch
oligom
design
optimis
excis
exon
normal
dystrophin
mrna
remov
mutat
exon
effici
mutationspecif
oligom
conclus
rais
possibl
mismatch
ao
could
still
therapeut
applic
case
negat
necess
produc
patientspecif
compound
antisens
oligom
ao
induc
exon
skip
emerg
promis
approach
reduc
sever
duchenn
muscular
dystrophi
dmd
progress
rapidli
concept
complet
sever
clinic
trial
therapi
use
ao
modifi
splice
prerna
process
dmdassoci
exon
remov
shorter
partial
function
becker
muscular
dystrophi
bmd
like
dystrophin
isoform
produc
commonli
splice
switch
ao
design
target
motif
normal
dystrophin
gene
transcript
appropri
sinc
common
type
dmd
mutat
delet
one
exon
normal
exon
flank
delet
must
remov
restor
read
frame
addit
may
assum
normal
exon
gener
difficult
dislodg
mutat
counterpart
sinc
full
complement
splice
motif
present
former
diseasecaus
gene
lesion
silent
polymorph
small
intraexon
delet
insert
substitut
may
occur
within
oligom
anneal
region
impact
upon
splice
control
motif
could
potenti
alter
efficaci
ao
design
optimis
normal
dystrophin
gene
transcript
data
human
genom
project
suggest
singl
nucleotid
polymorph
snp
occur
everi
base
http
wwwornlgovscitechresourceshumangenom
faqsnpsshtml
although
distribut
snp
nonrandom
incid
mean
patient
may
harbour
snp
target
exon
given
dystrophin
exon
averag
bp
long
splice
switch
ao
design
patient
carri
intraexon
diseasecaus
mutat
approxim
chanc
gene
lesion
occur
within
ao
anneal
sequenc
consequ
even
dmd
boy
mutat
mrna
level
eg
genom
delet
exon
almost
certainli
uniqu
dystrophin
gene
differ
diseaseassoci
delet
breakpoint
well
nondiseas
associ
dna
variat
proteincod
noncod
region
unexpect
dmd
boy
could
respond
induc
exon
skip
uniqu
manner
reason
develop
optim
exon
skip
strategi
dmd
mutat
best
evalu
cell
patient
subtl
dystrophin
gene
chang
intraexon
insertiondeletionssubstitut
collect
repres
less
case
spread
across
dystrophin
gene
make
lower
prioriti
immedi
clinic
develop
amen
mutat
subtyp
delet
hotspot
anticip
acceler
develop
oligom
induc
exon
skip
therapi
dmd
wish
develop
effect
exon
skip
strategi
mani
differ
dmd
mutat
possibl
describ
wilton
et
al
optimis
ao
exclud
exon
dystrophin
transcript
exclud
first
last
exon
focus
upon
refin
ao
design
preclin
test
dmd
patient
cell
line
present
optim
oligom
skip
exon
report
unexpect
find
mismatch
oligom
induc
effici
exon
exclus
cell
young
patient
singl
base
insert
exon
insert
lie
within
optim
ao
target
sequenc
oligom
consist
modifi
base
phosphorothio
backbon
synthes
expedit
synthes
appli
biosystem
melbourn
australia
describ
adam
et
al
ao
sequenc
shown
tabl
ao
nomenclatur
accord
mann
et
al
optim
sequenc
excis
exon
prepar
suppli
avi
biopharma
inc
bothel
wa
phosphorodiamid
morpholino
oligom
pmo
conjug
cellpenetr
peptid
ppmok
normal
human
myoblast
prepar
describ
rando
et
al
deidentifi
muscl
biopsi
obtain
inform
consent
elect
surgeri
depart
neuropatholog
royal
perth
hospit
similarli
donat
inform
consent
deidentifi
fibroblast
obtain
dmd
patient
harbour
frame
shift
mutat
exon
insert
fibroblast
cultur
dmem
invitrogen
melbourn
australia
supplement
foetal
calf
serum
fc
serana
bunburi
australia
gibco
melbourn
australia
uml
penicillin
invitrogen
mgml
streptomycin
invitrogen
ngml
amphotericin
b
sigma
sydney
australia
fibroblast
convert
myoblast
forc
myogenesi
transfect
myod
express
adenoviru
differenti
low
serum
media
briefli
patient
fibroblast
cultur
confluenc
wash
pb
detach
trypsin
wv
gibco
inactiv
media
contain
fc
pellet
centrifug
g
resuspend
dmem
supplement
hors
serum
myod
adenovir
vector
multipl
infect
nineti
six
hour
treatment
myod
adenovir
vector
fibroblast
transfect
ao
use
human
tissu
approv
univers
western
australia
human
ethic
committe
approv
number
ra
normal
myoblast
prolifer
differenti
describ
previous
hard
et
al
cell
plate
cellswel
well
plate
sequenti
pretreat
hour
ml
poli
dlysin
sigma
matrigel
bd
bioscienc
sydney
australia
transfect
lipoplex
lipofectamin
ww
invitrogen
optimem
media
gibco
per
manufactur
instruct
ppmok
solut
warm
minut
dilut
optimem
media
indic
appli
directli
adher
cell
total
rna
harvest
h
transfect
duplic
well
use
trizol
invitrogen
accord
manufactur
instruct
resuspend
steril
water
baxter
healthcar
sydney
australia
approxim
ng
total
rna
use
tabl
gel
analysi
imag
sequenc
pcr
product
resolv
agaros
gel
tae
buffer
rel
exon
skip
effici
estim
densitometri
full
length
ao
induc
pcr
product
imag
captur
chemismart
system
vilber
lourmat
franc
describ
previous
necessari
ident
induc
transcript
confirm
band
stab
isol
purif
templat
use
ultraclean
spin
column
mobio
carlsbad
ca
dna
sequenc
use
bigdy
termin
chemistri
appli
biosystem
per
manufactur
instruct
sequenc
conduct
lotterywest
state
biomed
facil
genom
perth
australia
western
blot
perform
use
protocol
deriv
cooper
et
al
nicholson
et
al
cell
harvest
trypsinis
day
transfect
place
treatment
buffer
mg
wet
pellet
weight
consist
mm
trishcl
ph
sd
glycerol
mm
pmsf
mm
dithiothreitol
bromophenol
blue
wv
proteas
inhibitor
cocktail
treatment
buffer
sigma
sampl
vortex
briefli
sonic
second
time
set
ultrason
processor
sonic
newtown
ct
heat
minut
sampl
electrophores
trisbisglycin
sd
gradient
gel
ph
stack
gel
ph
gel
content
electrophoret
transfer
fluorotransw
pvdf
membran
pall
melbourn
australia
overnight
transfer
buffer
without
methanol
dystrophin
detect
monoclon
antidystrophin
novocastra
newcastleupontyn
uk
appli
dilut
hour
room
temperatur
detect
perform
use
western
breez
kit
per
manufactur
instruct
invitrogen
enhanc
chemiluminesc
reaction
detect
directli
chemismart
gel
document
system
vilber
lourmat
use
chemicapt
softwar
imag
acquisit
softwar
imag
analysi
splice
motif
predictor
program
ese
finder
rescu
ese
use
predict
put
exon
splice
enhanc
ese
exon
figur
anneal
coordin
ao
rel
predict
ese
posit
indic
design
target
predict
splice
motif
dystrophin
exon
tabl
figur
transfect
normal
human
myoblast
figur
normal
cell
ao
test
demonstr
robust
skip
exon
nm
effect
lower
concentr
nm
figur
show
level
exon
skip
myod
convert
patient
fibroblast
treatment
panel
ao
target
exon
donor
splice
site
induc
degre
exon
skip
effici
patient
cell
figur
induc
similar
level
exon
excis
patient
normal
cell
wherea
perform
better
patient
cell
normal
cell
concentr
test
figur
target
region
dystrophin
exon
encompass
caus
mutat
sinc
mismatch
oligom
gener
effect
exon
skip
subsequ
examin
patient
mutat
direct
dna
sequenc
confirm
origin
diagnosi
singl
base
insert
base
begin
exon
figur
mutat
occur
base
downstream
end
rais
question
might
influenc
ao
efficaci
figur
investig
design
mutat
specif
ao
target
coordin
ao
produc
patientspecif
ao
perfect
complementar
anneal
patient
dystrophin
transcript
figur
tabl
surprisingli
transfect
patient
cell
show
perfect
complementar
essenti
effici
exon
skip
case
figur
although
addit
base
make
littl
differ
compar
normal
cell
despit
mismatch
figur
patient
cell
reduc
effici
exon
skip
particularli
evid
lower
transfect
concentr
figur
dmd
patient
fibroblast
convert
myoblast
forc
myogenesi
transfect
k
ie
ppmok
chemistri
untreat
myod
convert
dmd
fibroblast
normal
myoblast
predomin
pcr
product
gener
k
treat
patient
control
myoblast
figur
confirm
exclus
exon
amplicon
figur
dmd
patient
whole
exon
delet
duplic
potenti
treat
excis
normal
exon
occur
nearnorm
context
reason
unaffect
normal
human
myoblast
routin
use
develop
optimis
spliceswitch
ao
sequenc
previous
shown
ao
effect
normal
cell
gener
also
effect
patient
cell
howev
recent
report
intraexon
chang
influenc
effici
aomedi
splice
manipul
panel
ao
design
target
human
dystrophin
exon
appli
patient
cell
carri
singl
base
insert
induc
exon
excis
dmdcaus
gene
lesion
alter
exon
splice
motif
determin
silico
analysi
unexpectedli
anneal
across
insert
therefor
mismatch
induc
robust
exon
skip
compar
profil
exon
skip
induc
normal
cell
appear
twice
effect
patient
cell
concentr
test
enhanc
exon
skip
patient
cell
would
due
infram
ao
induc
transcript
longer
subject
nonsens
mediat
decay
nmd
evas
nmd
would
increas
mrna
half
life
transcript
miss
exon
therebi
increas
figur
confirm
patient
dystrophin
mutat
potenti
effect
ao
anneal
dystrophin
insert
mutat
confirm
direct
sequenc
mutat
occur
within
anneal
site
suggest
number
potenti
scenario
bind
includ
perfect
complementar
normal
dystrophin
mrna
b
singl
base
bulg
mrna
bind
patient
mrna
c
perfect
complementar
patient
mrna
singl
base
bulg
oligom
bind
normal
mrna
e
specul
mismatch
oligom
perform
effect
patient
cell
comparison
mutat
specif
previou
mismatch
oligom
studi
us
other
util
sequenc
mismatch
base
insert
delet
within
oligom
mrna
duplex
oligom
anneal
across
singl
base
insert
would
presum
loopout
andor
alter
secondari
structur
premrna
compromis
exon
recognit
select
exon
skip
induc
patientspecif
oligom
compar
gener
transfect
origin
optim
normal
cell
reevalu
oligom
design
laboratori
includ
select
mismatch
wellstudi
splice
switch
oligom
determin
effect
uniqu
mutat
reflect
gener
mechan
eg
mirna
bind
seed
sequenc
target
gene
transcript
test
oligom
patient
cell
appropri
way
determin
patientspecif
mutat
polymorph
compromis
ao
efficaci
event
diminish
oligom
efficaci
altern
sequenc
evalu
data
report
us
other
report
mismatch
ao
compromis
exon
skip
effici
predict
person
oligom
optim
normal
cell
match
patient
sequenc
would
enhanc
efficaci
howev
prove
otherwis
case
present
person
induc
exon
skip
normal
patient
cell
markedli
lower
level
mismatch
oligom
design
normal
dystrophin
coordin
detect
dystrophin
protein
follow
induc
exon
skip
dmd
fibroblast
undergon
forc
myogenesi
myod
adenoviru
technic
challeng
unabl
demonstr
dystrophin
western
blot
treatment
order
confirm
efficaci
mismatch
oligom
chemistri
specif
forc
myogen
dmd
cell
transfect
oligom
sequenc
prepar
ppmok
effici
exon
skip
detect
dystrophin
protein
induc
k
treatment
indic
effect
could
also
achiev
morpholino
oligom
chemistri
contempl
use
custom
ppmok
mutat
cost
compound
restrict
applic
initi
exon
skip
treat
dmd
appli
delet
within
mutat
hotspot
despit
fact
nearli
half
dystrophin
exon
infram
therefor
mani
intraexon
mutat
could
address
singl
exon
skip
although
mani
exon
highli
amen
target
oligom
intervent
incent
pursu
target
limit
fact
infram
exon
restor
commonli
encount
exon
delet
frameshift
intraexon
mutat
spread
across
gene
promin
hotspot
furthermor
presenc
intraexon
mutat
snp
may
increas
decreas
exon
skip
efficaci
alter
splice
motif
directli
compromis
oligom
anneal
impli
patient
may
requir
mutationspecif
oligom
design
toxicolog
safeti
valid
add
signific
cost
bring
ao
clinic
even
singl
base
chang
eg
personalis
approv
ao
design
requir
valid
show
level
personalis
medicin
may
necessari
case
